No single ticker was named. Genomics ETFs are the exposure this bearish thesis argues against, most actionable for readers who already hold them. Not a recommendation.
FDA skepticism on external controls for gene therapy
The case was made that the FDA's recent stance against using external control groups for AMT-130 could close a critical pathway for developing gene therapies in rare neurodegenerative diseases.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.